ReviewTranslational cancer research2020
EGFR exon 20 insertion mutations in non-small cell lung cancer.
Review in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.Targeted oncology · 2022Pooled it
- Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data.BMC pulmonary medicine · 2026Article
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
- Inhalable Therapeutics in Lung Cancer: Overcoming Barriers for Effective Treatment.AAPS PharmSciTech · 2026Review
- Article
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- EGFR mutations in sinonasal squamous neoplasms: Novel hotspot for exon 20 insertions.Virchows Archiv : an international journal of pathology · 2025Article
- Spectrum of rareNarra J · 2025Observational
- Efficacy and safety outcomes of emerging EGFR‑TKIs for patients with non‑small cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and meta‑analysis.Oncology letters · 2025Article
- Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer.Translational lung cancer research · 2025Article
- Emerging Targets in Non-Small Cell Lung Cancer.Lung Cancer (Auckland, N.Z.) · 2025Review
- New advances in the treatment of EGFR exon20ins mutant advanced NSCLC.American journal of cancer research · 2025Review
- The therapeutic potential of RNA m(6)A in lung cancer.Cell communication and signaling : CCS · 2024Review
- Multinational proficiency tests for EGFR exon 20 insertions reveal that the assay design matters.Scientific reports · 2024Article
- Review
- Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.Journal of cancer research and clinical oncology · 2023Article
- Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions.Biomedicines · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the epidermal growth factor receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.